INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 49m ago
HOUSE PTR8m ago
SEC 13F8m ago
ROBINHOOD CHAIN8m ago
Public company

ARDXARDELYX, INC.

CIK 0001437402

EDGAR filingsOpen in network
Disclosed transactions37
Buys / sells0 / 27
Max Insider Score39
Connections18with evidence

ARDX · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
32
KM
Kelliher MikeChief Business Officer
ARDXARDELYX, INC.
Open-market sale
SELL$7,722
2,002 sh
Aug 21, 2026Aug 25, 2026
traded Aug 21, 2026
+4dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Lobbied forevidence
    ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC)LDA Q1 2026 first quarter · Medicare/Medicaid · Aug 26, 2026
  • ← Lobbied forevidence
    THORN RUN PARTNERSLDA Q1 2026 first quarter · Health issues · Aug 26, 2026
  • ← Lobbied forevidence
    THE MCMANUS GROUPLDA Q2 2026 second quarter · Medicare/Medicaid · Aug 26, 2026
32
WA
Williams Laura AChief Patient Officer
ARDXARDELYX, INC.
Open-market sale
SELL
$9,372
2,430 sh
Aug 21, 2026
Aug 25, 2026
traded Aug 21, 2026
+4d
SEC FORM 4

Evidence

32
RJ
Reilly Joseph JamesSee Remarks
ARDXARDELYX, INC.
Open-market sale
SELL$11K
2,872 sh
Aug 21, 2026Aug 25, 2026
traded Aug 21, 2026
+4dSEC FORM 4

Evidence

32
FD
Foster Eric DuaneChief Commercial Officer
ARDXARDELYX, INC.
Open-market sale
SELL$9,932
2,575 sh
Aug 21, 2026Aug 25, 2026
traded Aug 21, 2026
+4dSEC FORM 4

Evidence

32
FD
Foster Eric DuaneChief Commercial Officer
ARDXARDELYX, INC.
Open-market sale
SELL$13K
3,389 sh
Aug 21, 2026Aug 25, 2026
traded Aug 21, 2026
+4dSEC FORM 4

Evidence

32
WA
Williams Laura AChief Patient Officer
ARDXARDELYX, INC.
Open-market sale
SELL$6,688
1,734 sh
Aug 21, 2026Aug 25, 2026
traded Aug 21, 2026
+4dSEC FORM 4

Evidence

32
HS
Hohenleitner SusanChief Financial Officer
ARDXARDELYX, INC.
Open-market sale
SELL$6,009
1,558 sh
Aug 21, 2026Aug 25, 2026
traded Aug 21, 2026
+4dSEC FORM 4

Evidence

32
WA
Williams Laura AChief Patient Officer
ARDXARDELYX, INC.
Open-market sale
SELL$13K
3,486 sh
Aug 21, 2026Aug 25, 2026
traded Aug 21, 2026
+4dSEC FORM 4

Evidence

32
WA
Williams Laura AChief Patient Officer
ARDXARDELYX, INC.
Open-market sale
SELL$12K
3,089 sh
Aug 21, 2026Aug 25, 2026
traded Aug 21, 2026
+4dSEC FORM 4

Evidence

39
BP
Brady James ParkerChief Human Resources Officer
ARDXARDELYX, INC.
Open-market sale
SELL$51K
13.2K sh
Aug 21, 2026Aug 25, 2026
traded Aug 21, 2026
+4dSEC FORM 4

Evidence

32
RJ
Reilly Joseph JamesSee Remarks
ARDXARDELYX, INC.
Open-market sale
SELL$4,281
1,110 sh
Aug 21, 2026Aug 25, 2026
traded Aug 21, 2026
+4dSEC FORM 4

Evidence

32
FD
Foster Eric DuaneChief Commercial Officer
ARDXARDELYX, INC.
Open-market sale
SELL$10K
2,598 sh
Aug 21, 2026Aug 25, 2026
traded Aug 21, 2026
+4dSEC FORM 4

Evidence

32
KM
Kelliher MikeChief Business Officer
ARDXARDELYX, INC.
Open-market sale
SELL$12K
3,104 sh
Aug 21, 2026Aug 25, 2026
traded Aug 21, 2026
+4dSEC FORM 4

Evidence

32
KM
Kelliher MikeChief Business Officer
ARDXARDELYX, INC.
Open-market sale
SELL$10K
2,652 sh
Aug 21, 2026Aug 25, 2026
traded Aug 21, 2026
+4dSEC FORM 4

Evidence

32
BP
Brady James ParkerChief Human Resources Officer
ARDXARDELYX, INC.
Open-market sale
SELL$7,621
1,976 sh
Aug 21, 2026Aug 25, 2026
traded Aug 21, 2026
+4dSEC FORM 4

Evidence

11
WA
Williams Laura AChief Patient Officer
ARDXARDELYX, INC.
Open-market sale · 10b5-1 plan
SELL$490K
81.9K sh
Jun 18, 2026Jun 22, 2026
traded Jun 18, 2026
+4dSEC FORM 4

Evidence

0
WA
Williams Laura AChief Patient Officer
ARDXARDELYX, INC.
Option exercise · 10b5-1 plan
M$31K
31.0K sh
Jun 18, 2026Jun 22, 2026
traded Jun 18, 2026
+4dSEC FORM 4

Evidence

0
WA
Williams Laura AChief Patient Officer
ARDXARDELYX, INC.
Option exercise · 10b5-1 plan
M—
31.0K sh
Jun 18, 2026Jun 22, 2026
traded Jun 18, 2026
+4dSEC FORM 4

Evidence

9
BM
Bhanji MunaDirector
ARDXARDELYX, INC.
Grant or award
A—
39.7K sh
Jun 16, 2026Jun 18, 2026
traded Jun 16, 2026
+2dSEC FORM 4

Evidence

13
CO
Cadoret-Manier OnaizaDirector
ARDXARDELYX, INC.
Grant or award
A—
26.5K sh
Jun 16, 2026Jun 18, 2026
traded Jun 16, 2026
+2dSEC FORM 4

Evidence

9
PM
Parsey MerdadDirector
ARDXARDELYX, INC.
Grant or award
A—
39.7K sh
Jun 16, 2026Jun 18, 2026
traded Jun 16, 2026
+2dSEC FORM 4

Evidence

13
BM
Bhanji MunaDirector
ARDXARDELYX, INC.
Grant or award
A—
26.5K sh
Jun 16, 2026Jun 18, 2026
traded Jun 16, 2026
+2dSEC FORM 4

Evidence

17
PM
Parsey MerdadDirector
ARDXARDELYX, INC.
Grant or award
A—
26.5K sh
Jun 16, 2026Jun 18, 2026
traded Jun 16, 2026
+2dSEC FORM 4

Evidence

9
CO
Cadoret-Manier OnaizaDirector
ARDXARDELYX, INC.
Grant or award
A—
39.7K sh
Jun 16, 2026Jun 18, 2026
traded Jun 16, 2026
+2dSEC FORM 4

Evidence

36
FD
Foster Eric DuaneChief Commercial Officer
ARDXARDELYX, INC.
Open-market sale
SELL$20K
3,166 sh
May 21, 2026May 22, 2026
traded May 21, 2026
+1dSEC FORM 4

Evidence

36
HS
Hohenleitner SusanChief Financial Officer
ARDXARDELYX, INC.
Open-market sale
SELL$9,119
1,455 sh
May 21, 2026May 22, 2026
traded May 21, 2026
+1dSEC FORM 4

Evidence

36
RJ
Reilly Joseph JamesSee Remarks
ARDXARDELYX, INC.
Open-market sale
SELL$17K
2,683 sh
May 21, 2026May 22, 2026
traded May 21, 2026
+1dSEC FORM 4

Evidence

36
BP
Brady James ParkerChief Human Resources Officer
ARDXARDELYX, INC.
Open-market sale
SELL$12K
1,846 sh
May 21, 2026May 22, 2026
traded May 21, 2026
+1dSEC FORM 4

Evidence

36
RJ
Reilly Joseph JamesSee Remarks
ARDXARDELYX, INC.
Open-market sale
SELL$6,493
1,036 sh
May 21, 2026May 22, 2026
traded May 21, 2026
+1dSEC FORM 4

Evidence

36
KM
Kelliher MikeChief Business Officer
ARDXARDELYX, INC.
Open-market sale
SELL$12K
1,870 sh
May 21, 2026May 22, 2026
traded May 21, 2026
+1dSEC FORM 4

Evidence

36
KM
Kelliher MikeChief Business Officer
ARDXARDELYX, INC.
Open-market sale
SELL$16K
2,478 sh
May 21, 2026May 22, 2026
traded May 21, 2026
+1dSEC FORM 4

Evidence

36
FD
Foster Eric DuaneChief Commercial Officer
ARDXARDELYX, INC.
Open-market sale
SELL$15K
2,405 sh
May 21, 2026May 22, 2026
traded May 21, 2026
+1dSEC FORM 4

Evidence

36
FD
Foster Eric DuaneChief Commercial Officer
ARDXARDELYX, INC.
Open-market sale
SELL$15K
2,427 sh
May 21, 2026May 22, 2026
traded May 21, 2026
+1dSEC FORM 4

Evidence

36
KM
Kelliher MikeChief Business Officer
ARDXARDELYX, INC.
Open-market sale
SELL$18K
2,900 sh
May 21, 2026May 22, 2026
traded May 21, 2026
+1dSEC FORM 4

Evidence

0
WA
Williams Laura AChief Patient Officer
ARDXARDELYX, INC.
Option exercise · 10b5-1 plan
M—
0 sh
Jan 8, 2026Jan 9, 2026
traded Jan 8, 2026
+1dSEC FORM 4

Evidence

15
WA
Williams Laura AChief Patient Officer
ARDXARDELYX, INC.
Open-market sale · 10b5-1 plan
SELL$349K
50.0K sh
Jan 8, 2026Jan 9, 2026
traded Jan 8, 2026
+1dSEC FORM 4

Evidence

3
WA
Williams Laura AChief Patient Officer
ARDXARDELYX, INC.
Option exercise · 10b5-1 plan
M$50K
50.0K sh
Jan 8, 2026Jan 9, 2026
traded Jan 8, 2026
+1dSEC FORM 4

Evidence

  • ← Lobbied forevidence
    CAPITOL CITY GROUP, LTD.LDA Q1Y 2026 first quarter · issues not listed · Aug 26, 2026
  • ← Lobbied forevidence
    LMH STRATEGIC SOLUTIONSLDA Q2 2026 second quarter · Health issues, Pharmacy · Aug 26, 2026
  • ← Lobbied forevidence
    THE HARPLE GROUP, LLCLDA Q1 2026 first quarter · Health issues · Aug 26, 2026
  • ← Lobbied forevidence
    CAPITOL COUNSEL LLCLDA 1TY 2026 first quarter · issues not listed · Aug 26, 2026
  • ← Lobbied forevidence
    JEFFREY J. KIMBELL & ASSOCIATES, INC.LDA Q1 2026 first quarter · Medicare/Medicaid, Health issues · Aug 26, 2026
  • ← Insider ofevidence
    Parsey MerdadDirector · Jun 18, 2026
  • ← Insider ofevidence
    Bhanji MunaDirector · Jun 18, 2026
  • ← Insider ofevidence
    Cadoret-Manier OnaizaDirector · Jun 18, 2026
  • ← Insider ofevidence
    Hohenleitner SusanChief Financial Officer · May 22, 2026
  • ← Insider ofevidence
    Kelliher MikeChief Business Officer · May 22, 2026
  • ← Insider ofevidence
    Foster Eric DuaneChief Commercial Officer · May 22, 2026
  • ← Insider ofevidence
    Reilly Joseph JamesSee Remarks · May 22, 2026
  • ← Insider ofevidence
    Brady James ParkerChief Human Resources Officer · May 22, 2026
  • ← Insider ofevidence
    Williams Laura AChief Patient Officer · Jan 9, 2026

    • Lobbying

    $1.56M reported · de-duplicated
    2026 Q2 $1.00M in-house2026 Q1 $560K in-house
    • CAPITOL CITY GROUP, LTD.—2026 Q1 · posted Aug 26, 2026 ·
    • THE HARPLE GROUP, LLC$20K2026 Q2 · posted Aug 26, 2026 · Health issues
    • In-house report$500K2026 Q2 · posted Aug 26, 2026 · Health issues
    • LMH STRATEGIC SOLUTIONS$30K2026 Q1 · posted Aug 26, 2026 · Health issues, Pharmacy
    • THORN RUN PARTNERS$60K2026 Q1 · posted Aug 26, 2026 · Health issues
    • LMH STRATEGIC SOLUTIONS$30K2026 Q2 · posted Aug 26, 2026 · Health issues, Pharmacy
    • THE MCMANUS GROUP$60K2026 Q2 · posted Aug 26, 2026 · Medicare/Medicaid
    • In-house report$560K2026 Q1 · posted Aug 26, 2026 · Health issues
    • THORN RUN PARTNERS$60K2026 Q2 · posted Aug 26, 2026 · Health issues
    • CAPITOL CITY GROUP, LTD.—2026 Q1 · posted Aug 26, 2026 ·
    • JEFFREY J. KIMBELL & ASSOCIATES, INC.$40K2026 Q2 · posted Aug 26, 2026 · Medicare/Medicaid, Health issues
    • THE HARPLE GROUP, LLC$20K2026 Q1 · posted Aug 26, 2026 · Health issues

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.